99 related articles for article (PubMed ID: 10796590)
1. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.
Patel M
Cochrane Database Syst Rev; 2000; (2):CD001093. PubMed ID: 10796590
[TBL] [Abstract][Full Text] [Related]
2. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.
Patel M; Lee CK
Cochrane Database Syst Rev; 2001; (3):CD001093. PubMed ID: 11686976
[TBL] [Abstract][Full Text] [Related]
3. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.
Patel M; Lee CK
Cochrane Database Syst Rev; 2005 Jan; (1):CD001093. PubMed ID: 15674874
[TBL] [Abstract][Full Text] [Related]
4. Conjugate vaccines for preventing meningococcal C meningitis and septicaemia.
Conterno LO; Silva Filho CR; Rüggeberg JU; Heath PT
Cochrane Database Syst Rev; 2006 Jul; (3):CD001834. PubMed ID: 16855979
[TBL] [Abstract][Full Text] [Related]
5. WITHDRAWN: Conjugate vaccines for preventing meningococcal C meningitis and septicaemia.
Conterno LO; da Silva Filho CR; Ruggeberg JU; Heath PT
Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD001834. PubMed ID: 21735387
[TBL] [Abstract][Full Text] [Related]
6. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A.
Erwa HH; Haseeb MA; Idris AA; Lapeyssonnie L; Sanborn WR; Sippel JE
Bull World Health Organ; 1973; 49(3):301-5. PubMed ID: 4211056
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of the meningococcal vaccine from Group C capsular polysaccharide].
González Enríquez J; García Comas L; Alcaide Jiménez JF; Sáenz Calvo A; Conde Olasagasti J
Rev Esp Salud Publica; 1997; 71(2):103-26. PubMed ID: 9546855
[TBL] [Abstract][Full Text] [Related]
8. Meningococcal serogroup C serum and salivary antibody responses to meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with bivalent and quadrivalent meningococcal polysaccharide vaccine.
Khalil M; Al-Mazrou Y; Findlow H; Chadha H; Bosch Castells V; Oster P; Borrow R
Vaccine; 2014 Sep; 32(43):5715-21. PubMed ID: 25151042
[TBL] [Abstract][Full Text] [Related]
9. Challenges for development of meningococcal vaccines in infants and children.
Deasy A; Read RC
Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
11. [Analysis for protection rate and antibody levels of epidemic cerebrospinal meningitis among children aged between 3-23 months in Liuzhou, in 2012].
Cui XL; Wu X; Li MQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1079-1083. PubMed ID: 28057112
[No Abstract] [Full Text] [Related]
12. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
[TBL] [Abstract][Full Text] [Related]
13. Salivary and Serum Antibody Response Against Neisseria meningitidis After Vaccination With Conjugate Polysaccharide Vaccines in Ethiopian Volunteers.
Bårnes GK; Workalemahu B; Kristiansen PA; Beyene D; Merdekios B; Fissiha P; Aseffa A; Caugant DA; Naess LM
Scand J Immunol; 2016 Aug; 84(2):118-29. PubMed ID: 27219622
[TBL] [Abstract][Full Text] [Related]
14. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine.
Wahdan MH; Rizk F; el-Akkad AM; el-Ghoroury AA; Hablas R; Girgis NI; Amer A; Boctar W; Sippel JE; Gotschlich EC; Triau R; Sanborn WR; Cvjetanović B
Bull World Health Organ; 1973 Jun; 48(6):667-73. PubMed ID: 4206451
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of safety of meningococcal group AC bivalent polysaccharide conjugate vaccine in children aged 5-24 months old].
Zhou H; Wang JY; Tan Y; Lü HY; Wang M; Cai QC; Zhang HZ
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):920-3. PubMed ID: 24378132
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
Peltola H; Mäkelä H; Käyhty H; Jousimies H; Herva E; Hällström K; Sivonen A; Renkonen OV; Pettay O; Karanko V; Ahvonen P; Sarna S
N Engl J Med; 1977 Sep; 297(13):686-91. PubMed ID: 408682
[TBL] [Abstract][Full Text] [Related]
17. [Critical review of control strategies for meningococcal meningitis epidemics in Sub-Saharan Africa].
Chippaux JP; Debois H; Saliou P
Bull Soc Pathol Exot; 2002 Mar; 95(1):37-44. PubMed ID: 12012963
[TBL] [Abstract][Full Text] [Related]
18. Prevention of bacterial meningitis: an overview of Cochrane systematic reviews.
Prasad K; Karlupia N
Respir Med; 2007 Oct; 101(10):2037-43. PubMed ID: 17706408
[TBL] [Abstract][Full Text] [Related]
19. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.
Wahdan MH; Sallam SA; Hassan MN; Abdel Gawad A; Rakha AS; Sippel JE; Hablas R; Sanborn WR; Kassem NM; Riad SM; Cvjetanović B
Bull World Health Organ; 1977; 55(6):645-51. PubMed ID: 413639
[TBL] [Abstract][Full Text] [Related]
20. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
